Gender difference on five-year outcomes of EXCEL biodegradable polymer-coated sirolimus-eluting stents implantation: Results from the CREATE study

Chinese Medical Journal

Volumn 126, Issue 6, 2013, Pages 1039-1045

  Zhang, Lei ^a   Qiao, Bing ^a   Han, Ya Ling ^a,d   Li, Yi ^a   Xu, Kai ^a   Zhang, Quan Yu ^a   Yang, Li Xia ^b   Liu, Hui Liang ^a   Xu, Bo ^c   Gao, Run Lin ^c  

^a SHENYANG NORTHERN HOSPITAL   (China)

^b KUNMING GENERAL HOSPITAL   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d FUWAI HOSPITAL   (China)

Author keywords

Angioplasty; Percutaneous coronary intervention; Sex factor; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN;

ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; REVASCULARIZATION; RISK FACTOR; SEX DIFFERENCE; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; SEX FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84876930036     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123430     Document Type: Article

References (34)

1. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, et al, on behalf of European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169-1179.
2. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993; 87: 720-727.
3. Malenka DJ, O'Connor GT, Quinton H, Wennberg D, Robb JF, Shubrooks S, et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13 061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 1996; 94 (9 Suppl): II99-I104.
4. Jacobs AK, Kelsey SF, Yeh W, Holmes DR Jr, Block PC, Cowley MJ, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood Institute. Am J Cardiol 1997; 80: 979-984.
5. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98: 1279-1285.
6. Onuma Y, Kukreja N, Daemen J, Garcia-Garcia HM, Gonzalo N, Cheng JM, et al, Interventional Cardiologists of Thoraxcenter. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registnes. JACC Cardiovasc Interv 2009; 2: 603-610.
7. Duvernoy CS, Smith DE, Manohar P, Schaefer A, Klme-Rogers E, Share D, et al. Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Mchigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J 2010; 159: 677-683.
8. Han YL, Zhang L, Yang LX, Liu HL, Qu P, Li WM, et al. A new generation of biodegradable polymer-coated sirohmus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. EuroIntervention 2012; 8: 815-822.
9. Han Y, Jing Q, Li Y, Yang L, Liu H, Shang X, et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirohmus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc Interv 2012; 79: 211-216.
10. Han Y, Jmg Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and efficacy of biodegradable polymer-coated sirohmus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
11. Li Y, Han Y, Zhang L, Jing Q, Wang X, Yan G, et al. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus: Insight from the 4-year results of the CREATE study. Catheter Cardiovasc Interv 2012; Epub ahead of print.
12. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol 2001; 88: 848-852.
13. Argulian E, Patel AD, Abramson JL, Kulkarni A, Champney K, Palmer S, et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. Am J Cardiol 2006; 98: 48-53.
14. Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, et al. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv 2009; 74: 719-727.
15. Arnold AM, Mick MJ, Piedmonte MR, Simpfendorfer C. Gender differences for coronary angioplasty. Am J Cardiol 1994; 74: 18-21.
16. Bell MR, Grill DE, Garratt KN, Berger PB, Gersh BJ, Holmes DR Jr. Long-term outcome of women compared with men after successful coronary angioplasty. Circulation 1995; 91: 2876-2881.
17. Berger JS, Sanborn TA, Sherman W, Brown DL. Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention. Am Heart J 2006; 151: 1026-1031.
18. Robertson T, Kennard ED, Mehta S, Popma JJ, Carrozza JP Jr, King SB 3rd, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol 1997; 80: 26K-39K.
19. Kovacic JC, Mehran R, Karajgikar R, Baber U, Suleman J, Kim MC, et al. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv 2012; 80: 514-521.
20. Meredith I, Rothman M, Erghs A, Pankh K, Lotan C; E-Five Investigators. Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. Catheter Cardiovasc Interv 2011; 77: 993-1000.
21. Nakatani D, Ako J, Tremmel JA, Waseda K, Otake H, Koo BK, et al. Sex differences in neointimal hyperplasia following Endeavor zotarolimus-eluting stent implantation. Am J Cardiol 2011; 108: 912-917.
22. Tillmanns H, Waas W, Voss R, Grempels E, Hölschermann H, Haberbosch W, et al. Gender differences in the outcome of cardiac interventions. Herz 2005; 30: 375-389.
23. Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutanems coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACCNCDR). Am Heart J 2009; 157: 141-148.
24. Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Monce MC, Popma JJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol 2007; 50: 2111-2116.
25. Abbott D, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R, et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 99: 626-631.
26. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-specific outcomes after sirolimus-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45: 1180-1185.
27. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739.
28. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-513.
29. Valgimigh M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125: 2015-2026.
30. Stefamm GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, et al. Biodegradable polymer drug-eluting stents reduce the nsk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33: 1214-1222.
31. Peterson ED, Lansky AJ, Kramer J, Anstrom K, Lanzilotta MJ; National Cardiovascular Network Clinical Investigators. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol 2001; 88: 359-364.
32. Jacobs AK, Johnston JM, Haviland A, Brooks MM, Kelsey SF, Holmes DR Jr, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. JAm Coll Cardiol 2002; 39: 1608-1614.
33. Jacobs AK. The efficacy of drug-eluting stents in women: a window of opportunity. J Am Coll Cardiol Interv 2009; 2: 611-613.
34. Tizón-Marcos H, Bertrand OF, Rodés-Cabau J, Larose E, Gaudreault V, Bagur R, et al. Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes. Am Heart J 2009; 157: 740-745.